Search results for "thrombolytic therapy"

showing 10 items of 61 documents

Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes

2006

To determine the long-term mortality of patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) that are eligible versus those not eligible in randomized controlled trials (RCT), and how each exclusion criteria is associated with outcome.Common causes of exclusion in six published RCT on intravenous antithrombotic therapy were prospectively assessed in a cohort of 452 consecutive patients with NSTEACS that were followed for up to 3 years.Forty-one percent of patients had one or more exclusion criteria establishing the ineligible group. These patients were older, more likely to have coronary risk factors, ischemic ECG changes, heart failure at admission, higher creatinine l…

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentRevascularizationlaw.inventionElectrocardiographyRandomized controlled trialRisk FactorslawInternal medicinemedicineHumansThrombolytic TherapyProspective StudiesAcute Coronary SyndromeProportional Hazards ModelsRandomized Controlled Trials as TopicEjection fractionbusiness.industryPatient SelectionMortality rateST elevationmedicine.diseaseSurgeryClinical trialTreatment OutcomeEchocardiographyCohortFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion.

1995

Studies showed that endothelin-1 (ET-1) was increased in the acute myocardial infarction (AMI). Experimental studies reported that captopril was able to reduce ET-1 secretion, and that ET-1 was increased during reperfusion. This study was aimed to verify if captopril was able to reduce plasma ET-1 during thrombolysis in AMI. Seventy-three patients, hospitalized for suspected AMI within 4 h from the onset of symptoms suitable for thrombolysis (1st episode), Killip class 1-2, were randomized (double blind) into two groups: group 1 (37 pts), 8 F/29 M, received captopril, 6.25 mg, orally 15 min before thrombolysis. Group 2: (36 pts) 8 F/28 M, received placebo before thrombolysis. All patients m…

Malemedicine.medical_specialtyCaptoprilTime Factorsmedicine.medical_treatmentMyocardial InfarctionAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressureMyocardial ReperfusionPlaceboAnginaPlacebosElectrocardiographyDouble-Blind MethodHeart RateInternal medicineFibrinolysismedicineHumansThrombolytic TherapyMyocardial infarctionAngina UnstableCreatine KinaseKillip classbusiness.industryUnstable anginaEndothelinsCaptoprilThrombolysismedicine.diseaseRecombinant ProteinsSurgeryIsoenzymesTissue Plasminogen ActivatorCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational journal of cardiology
researchProduct

Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry).

2002

There is conflicting information about gender differences in presentation, treatment, and outcome after acute ST elevation myocardial infarction (STEMI) in the era of thrombolytic therapy and primary percutaneous coronary intervention. From June 1994 to January 1997, we enrolled 6,067 consecutive patients with STEMI admitted to 54 hospitals in southwest Germany in the Maximal Individual TheRapy of Acute myocardial infarction (MITRA), a community-based registry. Women were 9 years older than men, more often had hypertension, diabetes mellitus, and congestive heart failure, and had a history of previous myocardial infarction less often. Women had a longer prehospital delay (45 minutes), had a…

Malemedicine.medical_specialtyEmergency Medical Servicesmedicine.medical_treatmentMyocardial InfarctionInfarctionAngina PectorisAnginaReperfusion therapySex FactorsInternal medicineGermanymedicineHumansThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesAgedHeart Failurebusiness.industryPercutaneous coronary interventionThrombolysisOdds ratioMiddle Agedmedicine.diseaseSurvival AnalysisHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: Results From a Single-Center Cohort

2016

We present our single-center results on ultrasound-assisted thrombolysis (USAT) in patients with pulmonary embolism (PE) at intermediate high risk (IHR) and high risk (HR). Our study consisted of 75 patients with PE who underwent USAT (60 at IHR and 15 at HR). The median time delay from symptoms to USAT was 5 days. Ultrasound-assisted thrombolysis resulted in improvements in tricuspid annular plane systolic excursion; pulmonary artery (PA) systolic and mean pressures; Qanadli score; right to left ventricle diameter ratio and right to left atrial diameter ratio; and diameters of main, right, and left PA regardless of the baseline risk status ( P < .0001 for all). Death was documented in …

Malemedicine.medical_specialtyIohexolmedicine.medical_treatmentContrast Media030204 cardiovascular system & hematologySingle CenterCatheterization03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicineHumansThrombolytic Therapy030212 general & internal medicineUltrasonography InterventionalRetrospective Studiesbusiness.industryRetrospective cohort studyThrombolysisMiddle Agedmedicine.diseasePulmonary embolismTreatment Outcomemedicine.anatomical_structureEchocardiographyVentricleCohortPulmonary arteryCardiologyFemaleIohexolPulmonary EmbolismTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusinessmedicine.drugAngiology
researchProduct

Post-Reperfusion Lymphopenia and Microvascular Obstruction in ST-Segment Elevation Acute Myocardial Infarction

2009

The presence of microvascular obstruction after ST-segment elevation acute myocardial infarction is associated with a poor outcome. The pathophysiology of this process has not been fully defined. The aim of this study was to investigate the relationship between post-reperfusion lymphopenia and microvascular obstruction.This prospective study involved 212 patients with a first ST-segment elevation acute myocardial infarction who underwent reperfusion with thrombolytic agents or primary angioplasty and who had an open infarct-related artery. Serial measurements of lymphocyte, neutrophil and monocyte counts were taken. Cardiac magnetic resonance was used to detect microvascular obstruction dur…

Malemedicine.medical_specialtyMyocardial InfarctionInfarctionLymphopeniaInternal medicineHumansMedicineST segmentThrombolytic TherapyProspective StudiesVascular DiseasesMyocardial infarctionProspective cohort studybusiness.industryAngioplastyElectrocardiography in myocardial infarctionGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureMicrovesselsCardiologyFemalebusinessPerfusionTIMIArteryRevista Española de Cardiología (English Edition)
researchProduct

Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.

1999

Abstract Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. Methods and Results Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal card…

Malemedicine.medical_specialtyStreptokinasemedicine.medical_treatmentMyocardial InfarctionAnginaCohort StudiesFibrinolytic AgentsRecurrenceAngioplastyInternal medicineMedicineHumansStreptokinaseThrombolytic TherapyMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassAgedbusiness.industryOdds ratioThrombolysisMiddle Agedmedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorConfidence intervalRecombinant ProteinsCerebrovascular DisordersCardiologySaruplaseFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Prognostic value of ST-segment resolution after rescue percutaneous coronary intervention. Data from the RICO survey

2008

Objectives: The goal of the present study was to test the impact of ST segment resolution (STR) after rescue percutaneous coronary intervention (PCI) on the short-term prognosis. Background: The prognostic value of STR after rescue PCI for acute ST elevation myocardial infarction (STEMI) remains undetermined. Methods: From the French regional database, we analyzed 168 consecutive patients with STEMI and failed lysis, defined by <50 percent STR, who underwent rescue PCI. Patients were classified into two groups according to the degree of STR from the maximal ST-elevation measured on the single worst ECG lead before lysis and after rescue PCI: the without STR group (<50% STR) vs. the with STR…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionRisk AssessmentElectrocardiographyCoronary CirculationInternal medicineOdds RatiomedicineHumansST segmentThrombolytic TherapyRadiology Nuclear Medicine and imagingProspective StudiesRegistriesTreatment Failurecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryProspective cohort studyAgedIntra-Aortic Balloon Pumpingmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle AgedPrognosismedicine.diseaseeye diseasesSurgeryTreatment OutcomeCardiovascular DiseasesHealth Care SurveysConventional PCICardiologyFemaleStentsFranceCardiology and Cardiovascular MedicinebusinessElectrocardiographyTIMICatheterization and Cardiovascular Interventions
researchProduct

Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany.

2019

Abstract Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death; systemic thrombolysis is potentially lifesaving treatment in patients presenting with haemodynamic instability. We investigated trends in the use of systemic thrombolysis and the outcome of patients with acute PE. Methods and results We analysed data on the characteristics, comorbidities, treatment, and in-hospital outcome of 885 806 PE patients in Germany between 2005 and 2015. Incidence of acute PE was 99/100 000 population/year and increased from 85/100 000 in 2005 to 109/100 000 in 2015 [β 0.32 (0.26–0.38), P &amp;lt; 0.001]. During the same period, in-hospital case fatality rates decreased fro…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicineGermanyCase fatality ratemedicineHumansThrombolytic TherapyCardiopulmonary resuscitationHospital MortalityeducationCause of deathAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryMortality rate030229 sport sciencesThrombolysisMiddle Agedmedicine.diseasePulmonary embolismTreatment OutcomeAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentFollow-Up StudiesEuropean heart journal
researchProduct

Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis.

2001

Abstract Background In patients with acute myocardial infarction treated with thrombolysis, longer times to treatment are associated with increasingly worse clinical outcome. This relation may be different for treatment with primary angioplasty. Methods We analyzed the pooled data of the German acute myocardial infarction registries Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and Myocardial Infarction Registry (MIR) to determine the influence of prehospital delays on hospital mortality rates. Primary angioplasty was performed in 1063 patients and thrombolysis in 7552 patients. Results In patients treated with thrombolysis, in-hospital time to treatment was constantly 3…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTime to treatmentPrimary angioplastyMyocardial InfarctionStatistics NonparametricInternal medicineFibrinolysismedicineHumansIn patientThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesChemotherapyChi-Square Distributionbusiness.industryMortality rateThrombolysisMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonAmerican heart journal
researchProduct